How I Diagnose Primary Myelofibrosis.
Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN) with a...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 24 results for 'primary myelofibrosis '
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
COVID-19 carries a high risk of severe disease course, particularly in patients with...
Read More
Prognostic Scores Validated for Additional Mutations in Secondary Myelofibrosis
Adding additional clinical and genetic information improved the performance of prognostic scores in secondary myelofibrosis, researchers in France report.
Read MoreMutations & Proliferative Pathways Drive Myelofibrosis Evolution
Myeloproliferative neoplasms (MPN) are marked by the overproduction of myeloid cells, driven by JAK2, CALR, and MPL mutations. A recent study aimed to explain how these mutations result in various MPN phenotypes by sequencing...
Read More
Is Pelabresib + Ruxolitinib the Paradigm-Shifting Combo Therapy for Myelofibrosis?
Pelabresib plus ruxolitinib has shown efficacy in the treatment responses of patients with myelofibrosis.
Read More
Pelabresib and Ruxolitinib Combination in Treatment-Naïve Myelofibrosis: MANIFEST Study Results
The following is a summary of “MANIFEST: Pelabresib in Combination With Ruxolitinib for...
Read More
Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to...
Read More
Momelotinib Yields Clinically Significant Improvement in Myelofibrosis
MONDAY, Feb. 6, 2023 (HealthDay News) — Treatment with momelotinib versus danazol yields...
Read MoreReduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase.
Accelerated-phase (AP) myelofibrosis, currently defined by circulating blasts 10-19%, usually confers very high risk for progression and poor outcome. The outcome of hematopoietic stem cell transplantation for AP myelofibrosis...
Read MoreAdvertisement
Febrile episode unmasking neuropsychiatric systemic lupus erythematosus with lytic lesions caused by secondary autoimmune myelofibrosis: Case report.
Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that...
Read MoreSafety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.
The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). The primary objective of phase 1b was to establish the maximum tolerated dose (MTD) and/or...
Read MoreStudy Confirms Prognostic Role of Certain Genetic Mutations
Myelofibrosis is characterized by mutations in the JAK–STAT pathway, specifically in the myeloproliferative neoplasm (MPN) driver genes JAK2, CALR, and MPL. However, patients often have mutations in other MPN-related genes,...
Read More
Myeloproliferative Disorders & Bone Homeostasis: The Role of Megakaryocytes
Myeloproliferative neoplasms (MPNs) are a diverse group of chronic hematological diseases caused...
Read More
Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
This study seeks to further characterize the clinicopathologic spectrum of DDX41-mutated...
Read More
Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study.
Lack of demonstrable mutations affecting , or driver genes within the spectrum of -negative...
Read More
Treatment outcome of Philadelphia chromosome negative myeloproliferative neoplasms: experience of a single developing country’s hematology-oncology centre.
Myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia...
Read More
Managing Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential...
Read More
Thrombosis among 1537 patients with JAK2 -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.
To explore the risk factors of thrombosis in patients with JAK2 -mutated myeloproliferative...
Read MoreMF Grade Does Not Impact Prognosis in Patients With MDS
Myelodysplastic syndrome (MDS) is a complex hematological malignancy, often presenting with myelofibrosis (MF) in 10% to 20% of cases. Although MF is recognized as an independent risk factor for MDS prognosis, it is not...
Read More
Ruxolitinib Cream: A Chance for Treatment Success for Patients With Mild Hidradenitis Suppurativa
Phase 2 trial results show reductions in the abscesses and inflammatory nodule count were induced by topical treatment with ruxolitinib versus vehicle.
Read More